Generation bio announces the presentation of preclinical data on ctlnp and iqdna at the esgct 31st annual congress

Cambridge, mass., oct. 22, 2024 (globe newswire) -- generation bio co. (nasdaq:gbio) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented data on its cell-targeted lipid nanoparticle (ctlnp) and immune-quiet dna (iqdna) platforms at the european society of gene and cell therapy (esgct) 31st annual congress.
GBIO Ratings Summary
GBIO Quant Ranking